Rapid Development of High-Level Resistance to Dolutegravir With Emergence of T97A Mutation in 2 Treatment-Experienced Individuals With Baseline Partial Sensitivity to Dolutegravir

Jomy M George; Safia S Kuriakose; Nicola Dee; Pam Stoll; Tahaniyat Lalani; Robin Dewar; Muhammad A Khan; Muhammad T Rehman; Zehava Grossman; Frank Maldarelli; Alice K Pau

doi:10.1093/ofid/ofy221

Rapid Development of High-Level Resistance to Dolutegravir With Emergence of T97A Mutation in 2 Treatment-Experienced Individuals With Baseline Partial Sensitivity to Dolutegravir

Open Forum Infect Dis. 2018 Sep 8;5(10):ofy221. doi: 10.1093/ofid/ofy221. eCollection 2018 Oct.

Authors

Affiliations

¹ Clinical Center, National Institutes of Health, Bethesda, Maryland.
² Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland.
³ Uniformed Services University of the Health Sciences, Bethesda, Maryland.
⁴ National Cancer Institute, Frederick, Maryland.
⁵ Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
⁶ National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.

Abstract

HIV integrase mutation T97A emerges after suboptimal therapy with integrase strand transfer inhibitors (INSTIs), but the contribution of T97A to dolutegravir resistance remains uncertain. Here we report >10-fold increase in dolutegravir resistance after the single addition of T97A in 2 individuals with prior INSTI resistance receiving dolutegravir salvage therapy.

Keywords: T97A; antiretroviral therapy; dolutegravir; drug resistance; salvage therapy.

Abstract

Grants and funding